建科院(300675) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥90,469,545.11, representing a year-on-year growth of 23.94%[7] - Net profit attributable to shareholders was ¥60,392.38, with a year-to-date net profit of ¥3,671,711.22, up 12.57% year-on-year[7] - The basic earnings per share for the reporting period was ¥0.0004, reflecting a 12.61% increase compared to the same period last year[7] - The company's operating revenue for the current period is CNY 60,785,837.42, compared to CNY 53,341,362.36 in the previous period, indicating a growth of approximately 14.3%[41] - The net profit for the current period is CNY 188,447.74, a significant recovery from a net loss of CNY 184,906.79 in the previous period[39] - The total profit for the current period is CNY 1,480,303.78, compared to a loss of CNY 461,989.25 in the previous period, showing a turnaround in profitability[39] - The total comprehensive income for the current period is CNY 188,447.74, compared to a loss of CNY 184,906.79 in the previous period, indicating a positive shift[39] - The basic and diluted earnings per share for the current period are both CNY 0.0004, recovering from a loss of CNY 0.0002 in the previous period[39] - The operating profit for the current period was ¥1,323,128.90, a turnaround from a loss of ¥616,725.59 in the previous period[47] Assets and Liabilities - Total assets at the end of the reporting period reached ¥839,977,162.80, an increase of 21.46% compared to the previous year[7] - The company's total assets increased to CNY 839,977,162.80 from CNY 691,584,901.89 at the beginning of the period, indicating strong growth[31] - Total liabilities rose to CNY 425,941,399.79, up from CNY 271,154,306.48, highlighting increased borrowing[31] - The total equity attributable to shareholders decreased to CNY 412,328,701.27 from CNY 418,172,867.42, indicating a slight reduction in shareholder value[31] Cash Flow - The net cash flow from operating activities showed a significant improvement, with a decrease of 95.67% year-to-date, resulting in -¥123,507.11[7] - The company reported a cash flow from operating activities of ¥-123,507.11, a significant improvement from ¥-25,605,193.52 in the previous period[51] - The company's cash inflow from operating activities totaled ¥374,142,499.55, compared to ¥235,589,449.39 in the previous period, reflecting a growth of 58.8%[51] - The net cash flow from operating activities for the third quarter was ¥16,041,569.14, compared to a negative cash flow of ¥19,257,752.80 in the same period last year[56] - Total cash inflow from operating activities was ¥321,380,657.10, significantly higher than ¥181,679,647.21 in the previous year[56] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,183[11] - The largest shareholder, Shenzhen Yuan Zhi Investment Co., Ltd., holds 42.86% of the shares, totaling 62,857,143 shares[11] - There were no repurchase transactions conducted by the top 10 shareholders during the reporting period[12] Research and Development - R&D expenses increased by 73.98% year-on-year, aligned with the progress of the national "13th Five-Year" key R&D projects[19] - Research and development expenses were CNY 2,981,781.75, compared to CNY 1,713,854.23 in the same period last year, reflecting a significant increase in investment in innovation[36] - The research and development expenses increased to CNY 2,809,368.92 from CNY 1,549,335.42, indicating a focus on innovation and product development[41] - Research and development expenses increased to ¥6,778,961.61, up 113.0% from ¥3,179,311.29 in the previous period, indicating a strong focus on innovation[49] Other Financial Metrics - The weighted average return on equity was 0.01%, down 16.19% from the previous year[7] - The company incurred asset impairment losses of CNY 1,643,396.16, which is a critical area of concern for future profitability[38] - The company received government subsidies amounting to ¥10,738,424.66, primarily for research projects and technology activities[8] - Other income rose by 90.81% year-on-year, mainly from subsidies related to the national R&D projects[19] - The company recorded an investment income of ¥5,121,686.37, with losses from joint ventures amounting to ¥429,962.25[49]